Medicine Discovery Research Articles

Osteosarcoma patient-derived orthotopic xenograft (PDOX) models for identification of novel and effective therapeutics.

228 Background: Osteosarcoma is the most common malignant primary tumor of bone and mainly occurs in young generations. Due to the heterogeneity, rarity, poor response rate to systemic therapy, and metastatic potential of osteosarcoma, individualized precision medicine and novel drug discovery are greatly needed. Toward this goal, we have established the patient-derived orthotopic xenograft (PDOX) mouse model with surgical orthotopic implantation for all major cancers. The PDOX models recapitulate human tumors better than subcutaneous-transplanted xenografts including patient-derived xenograft (PDX). Metastasis is observed to a greater extent in PDOX models due to the intact histology and correct-organ tumor micro-environment of the orthotopically implanted tissue. Therefore, the PDOX model is highly predictive of drug efficacy and useful for identifying effective drugs for tumors in which new drugs are difficult to develop. Methods: We have reported 18 osteosarcoma PDOX studies evaluating approved and experimental drugs since 2017. The present report reviews our research group’s experience with the osteosarcoma-PDOX model, and the power of the PDOX models to identify effective therapeutics. Results: Effective treatment for drug-resistant osteosarcoma includes regorafenib, as monotherapy, and temozolomide-irinotecan, trabectedin-irinotecan, sorafenib-everolimus, sorafenib-palbociclib, and olaratumab-doxorubicin-cisplatin, as combinations. Experimental therapy with recombinant methioninase, tumor-targeting S. typhimurium A1-R, or combinations of these agents and other drugs have shown surprising efficacy in the recalcitrant-osteosarcoma PDOX models. Conclusions: Owing to the high concordance of drug efficacy between patients and their corresponding PDOX models, these models provide improved and personalized treatment options for patients with osteosarcoma. The patient does not need to suffer from the potential drug toxicity and morbidity of ineffective chemotherapies. In an era of growing promise of new treatment and precision medicine, PDOX models can offer a unique opportunity to provide specific and individualized therapy and novel therapeutic options for osteosarcoma patients.

Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening.

Cancer is a leading cause of death worldwide. Around one-third of the total global cancer incidence and mortality are related to gastrointestinal (GI) cancers. Over the past few years, rapid developments have been made in patient-derived organoid (PDO) models for gastrointestinal cancers. By closely mimicking the molecular properties of their parent tumors in vitro, PDOs have emerged as powerful tools in personalized medicine and drug discovery. Here, we review the current literature on the application of PDOs of common gastrointestinal cancers in the optimization of drug treatment strategies in the clinic and their rising importance in pre-clinical drug development. We discuss the advantages and limitations of gastrointestinal cancer PDOs and outline the microfluidics-based strategies that improve the throughput of PDO models in order to extract the maximal benefits in the personalized medicine and drug discovery process.

Potential Bioactive Compounds of Plant as Anticancers in Lung Cancer A549 Cell Line: A Systematic Review

Cancer is one of the non-communicable diseases of global concern the world. Lung cancer is the leading cause of cancer death worldwide, and is the highest cause of death in both men and women at 18% of the world's 9.9 million cancer deaths. Efforts to prevent and cure cancer include using chemotherapy and anti-cancer drugs. Plants are rich in secondary metabolites which are byproducts of plant metabolism that have proven to be useful for the discovery and development of many medicines’ discovery and development of medicines. This article aims to review the potential of plant bioactive compounds that play a role in anticancer activity in lung cancer A549 cell line. In this journal review we used PubMed Centre database to identify articles published between 2014 and 2024. 10 studies were obtained from keywords concerning extracts bioactive compounds of plants used as lung anticancer against A549 cell line. From the results obtained, it was reported that plants containing active compounds such as polyphenols, terpenoids (oleanolic acid, ursolic acid, betulinate, ferruginol), flavonoids (tiliroside), and alkaloids can act as anticancer agents and are proven to inhibit the growth of lung cancer A549 cell line.

Antioxidant activity of Eucheuma cottonii Seaweed Extracts from Central Mawasangka Waters

Eucheuma cottonii is one type of seaweed that has the potential to be an antioxidant. This seaweed grows and is distributed in various waters of Indonesia, especially in Southeast Sulawesi. However, information regarding the antioxidant activity and the compound content of E. cottonii in this area is still limited. Therefore, this research aims to determine the compound and antioxidant activity profile in E. cottonii. The study used laboratory experimental methods. The research stages were preparation (seaweed sampling), extraction, qualitative phytochemical screening, and antioxidant assay. The initial identification of compounds using qualitative phytochemical screening methods with three extraction solvents: ethanol, ethyl acetate, and n-hexane. Meanwhile, the antioxidant test employed the DPPH (2,2-diphenyl-1-picrylhydrazyl) method. The results of qualitative phytochemical screening revealed that the seaweed extract of E. cottonii contains saponins, tannins, and terpenoids. The antioxidant assay using the DPPH method indicated that among the three extraction solvents used, ethanol extract exhibited a very strong antioxidant activity (with an IC50 of 30,036 ppm), compared to ethyl acetate extract (IC50 of 182,179 ppm) and n-hexane extract (IC50 of 641,454 ppm). This study concluded that E. cottonii seaweed has the potential to be developed as a source of natural antioxidants or raw material for the discovery of antioxidant medicines in the future.

Meaning, concept and application of bioinformatics

Bioinformatics, originating from the term coined in 1979 by Paulien Hogeweg and Ben Hesper, is a burgeoning interdisciplinary field at the nexus of biology, computer science, and information technology. It encompasses the collection, classification, storage, and analysis of vast biological datasets using computational methods, aiming to unravel the complexities of biological systems. This abstract provides a comprehensive overview of bioinformatics, emphasizing its definition, scope, branches, aims, research areas, databases, and applications, particularly highlighting its role in drug discovery through structural bioinformatics. Bioinformatics integrates diverse branches such as computational biology, genomics, proteomics, structural biology, systems biology, pharmacogenomics, and bioprogramming. Each branch applies mathematical modeling, molecular interactions analysis, or genomic data interpretation to advance understanding in biology and medicine. Key aims include applying advanced computational technologies to biological problems, presenting complex data clearly, and providing robust statistical tools for genomic analysis. The field also fosters collaborations across academic, commercial, and government sectors to leverage resources and expertise. Research areas span computational evolutionary analysis, genome annotation, gene expression analysis, cancer mutation studies, and comparative genomics, illuminating disease mechanisms and evolutionary relationships. Bioinformatics databases play a crucial role by storing and organizing biological data. Primary repositories like GenBank and the Protein Data Bank (PDB), secondary databases such as SWISS-Prot, and specialized databases support research and clinical applications by providing access to genomic, proteomic, and structural information. In drug discovery, structural bioinformatics techniques like homology modeling, molecular docking, and simulations predict protein structures, analyze interactions, and aid in designing therapies. These computational methods accelerate drug development, optimize drug-target interactions, and reduce costs associated with bringing new drugs to market. Overall, bioinformatics drives innovation in biological sciences and healthcare by leveraging computational methods to interpret biological data. As technology advances, bioinformatics will continue to play a pivotal role in addressing global health challenges, advancing personalized medicine, and facilitating groundbreaking discoveries in biology and medicine. The evolving field of bioinformatics promises continued growth and impact, shaping the future of biological research and its applications in improving human health and understanding the natural world.

Advances in Computational Methods for Drug Design: A Revolution in Pharmaceutical Development

Computational methods of drug design involve the use of various software and algorithms to predict the properties of drug molecules, screen for potential targets, and optimize drug candidates for therapeutic efficacy, it lowering the cost of drug research and development time. The discovery and development of a novel medicine is a lengthy, complex, expensive, and high-risk process that has no commercial counterpart. CADD has previously been used to uncover drugs that have gone through clinical trials and become innovative medicines for many ailments. CADD approaches are widely divided into two categories: structure-based drug design (SBDD) and ligand-based drug design (LBDD). SBDD is used when the three-dimensional structures of target proteins are available, while LBDD design is used in the absence of receptor 3D information and relies on knowledge of molecules that bind to the biological target of interest. Some applications in CADD are Lead Optimization, Virtual screening (VS), ADMET prediction, and toxicity prediction. Medicinal chemists use a variety of computational approaches to modify the chemical structure of a compound to maximize its in vitro activity, drug discovery is driven by the idea that a ligand with higher binding affinity to a target should be more efficacious than that with lower binding affinity to the same target. Target flexibility is one of the key issues that still need to be resolved in drug discovery. The majority of molecular docking tools give the ligand high flexibility, but they fix or give the protein's residues close to or inside the active site only limited flexibility. It is very difficult to provide complete molecular flexibility to the protein as this increases the space and time complexity of the computation. In conclusion, computational methods have revolutionized the field of drug design by enabling faster, more cost-effective, and more efficient drug discovery

Deciphering the Chemotherapeutic Role of the Aryl Hydrocarbon Receptor Antagonist Resveratrol against the High-Penetrance Genes of Triple-Negative Breast Cancer.

In addition to several other malignancies, the ligand-activated aryl hydrocarbon receptor (AhR) signaling pathway has been found to enhance the risk of triple-negative breast cancer (TNBC). Many natural compounds of pharmaceutical importance are identified as antagonistic exogenous ligands of AhR. The expressional lack of hormone receptors coupled with adverse prognosis leads to the absence of molecular-targeted therapy in TNBC. Hence, discovering low-cost therapeutic alternatives involving the identification of effective biomarkers is an urgent necessity. This study investigates the binding mechanism of resveratrol, a dietary exogenous AhR ligand against the high-penetrance genes in TNBC, viz., PALB2, TP53, PTEN, STK11, BRCA1, and BRCA2. Post-pharmacokinetic evaluation, molecular docking revealed the binding energy scores of resveratrol against the six TNBC high-penetrance receptors. The results obtained from docking were confirmed by molecular dynamics simulation including principal component analysis, calculation of total interaction energy, and free-energy landscape computation. PALB2 emerged as a promising therapeutic receptor of resveratrol. Furthermore, the PALB2-resveratrol binding dynamics were evaluated against olaparib, an FDA-approved standardized TNBC inhibitor. Our study reveals comparatively better chemistry of PALB2-resveratrol than PALB2-olaparib. Considering the current surge in the discovery of precision medicine in biomarker-based cancer therapeutics, this study proposes PALB2-resveratrol as a unique drug-receptor combination thus awaiting validation through in vitro studies.

Sophoridine exerts anti-arthritic effects on fibroblast-like synoviocytes and collagen-induced arthritis in rats.

The discovery of alternative medicines with fewer adverse effects is urgently needed for rheumatoid arthritis (RA). Sophoridine (SR), the naturally occurring quinolizidine alkaloid isolated from the leguminous sophora species, has been demonstrated to possess a wide range of pharmacological activities. However, the effect of SR on RA remains unknown. In this study, the collagen-induced arthritis (CIA) rat model and tumor necrosis factor alpha (TNFα)-induced fibroblast-like synoviocytes (FLSs) were utilized to investigate the inhibitory effect of SR on RA. The anti-arthritic effect of SR was evaluated using the CIA rat model in vivo and TNFα-stimulated FLSs in vitro. Mechanistically, potential therapeutic targets and pathways of SR in RA were analyzed through drug target databases and disease databases, and validation was carried out through immunofluorescence, immunohistochemistry, and Western blot. The in vivo results revealed that SR treatment effectively ameliorated synovial inflammation and bone erosion in rats with CIA. The in vitro studies showed that SR could significantly suppress the proliferation and migration in TNFα-induced arthritic FLSs. Mechanistically, SR treatment efficiently inhibited the activation of MAPKs (JNK and p38) and NF-κB pathways in TNFα-induced arthritic FLSs. These findings were further substantiated by Immunohistochemistry results in the CIA rat. SR exerts an anti-arthritic effect in CIA rats through inhibition of the pathogenic characteristic of arthritic FLSs via suppressing NF-κB and MAPKs (JNK and p38) signaling pathways. SR may have a great potential for development as a novel therapeutic agent for RA treatment.

Aphrodisiaca Activity of Momordica charantia L. and Areca catechu L. Ethanolic Extract Againts Blood Pressure and Body Weight of White Mile Rats

Advances in the discovery of herbal medicine and the increasing popularity of traditional medicines have made accessto traditional medicines in the market increasingly easier. Bitter melon and areca nut are known to have many benefits and potential as natural medicine. Previous studies has shown the aphrodisiac effects of these two natural ingredients. This research aimed to determine the additional effects, particularly on blood pressure and body weight of rats, when bitter melon and areca nut are administered as aphrodisiacs. Test animal retrieval techniques based on complete randomized design (RAL). Blood pressure was measured using the CODA® instrument on 25 white rats divided into 5 treatment groups, namely the control group (CMC Na 0.5 % 0.5 % w/v), the bitter melon extract group at a dose of 280 mg / kg BW, the areca nut extract group at a dose of 50 mg/kg 50 mg / kg BW, the mixed bitter melon and areca nut extracts group (1: 1), and the X-Gra® group. Blood pressure profiles measured included systolic and diastolic blood as well as changes in rat body weight before and after treatment. The results of the study of systole and diastole blood pressure parameters and rat body weight in groups I, II, III, IV, V analyzed using the Tukey HSD method obtained results that were not significantly different (sig 0.05) in all groups. Based on this study, it was concluded that the aphrodisiac activity of bitter melon and areca nut seeds did not significantly influence changes in blood pressure, systole and diastole, and body weight rats.

Meaning, Concept and Application of Bioinformatics

Bioinformatics, originating from the term coined in 1979 by Paulien Hogeweg and Ben Hesper, is a burgeoning interdisciplinary field at the nexus of biology, computer science, and information technology. It encompasses the collection, classification, storage, and analysis of vast biological datasets using computational methods, aiming to unravel the complexities of biological systems. This abstract provides a comprehensive overview of bioinformatics, emphasizing its definition, scope, branches, aims, research areas, databases, and applications, particularly highlighting its role in drug discovery through structural bioinformatics. Bioinformatics integrates diverse branches such as computational biology, genomics, proteomics, structural biology, systems biology, pharmacogenomics, and bioprogramming. Each branch applies mathematical modeling, molecular interactions analysis, or genomic data interpretation to advance understanding in biology and medicine. Key aims include applying advanced computational technologies to biological problems, presenting complex data clearly, and providing robust statistical tools for genomic analysis. The field also fosters collaborations across academic, commercial, and government sectors to leverage resources and expertise. Research areas span computational evolutionary analysis, genome annotation, gene expression analysis, cancer mutation studies, and comparative genomics, illuminating disease mechanisms and evolutionary relationships. Bioinformatics databases play a crucial role by storing and organizing biological data. Primary repositories like GenBank and the Protein Data Bank (PDB), secondary databases such as SWISS-Prot, and specialized databases support research and clinical applications by providing access to genomic, proteomic, and structural information. In drug discovery, structural bioinformatics techniques like homology modeling, molecular docking, and simulations predict protein structures, analyze interactions, and aid in designing therapies. These computational methods accelerate drug development, optimize drug-target interactions, and reduce costs associated with bringing new drugs to market. Overall, bioinformatics drives innovation in biological sciences and healthcare by leveraging computational methods to interpret biological data. As technology advances, bioinformatics will continue to play a pivotal role in addressing global health challenges, advancing personalized medicine, and facilitating groundbreaking discoveries in biology and medicine. The evolving field of bioinformatics promises continued growth and impact, shaping the future of biological research and its applications in improving human health and understanding the natural world. Keywords: Bioinformatics, Computational biology, Structural bioinformatics, Drug discovery, Genomics.

Twin Strep-Tag Modified CPT1A Mitochondrial Membrane Chromatography in Screening Lipid Metabolism Regulators.

Mitochondrial Membrane Chromatography (MMC) is a bioaffinity chromatography technique developed to study the interaction between target proteins embedded in the mitochondrial membrane and their ligand compounds. However, the MMC stationary phases (MMSP) prepared by chemical immobilization are prone to nonspecific binding in candidate agent screening inevitably. To address these challenges, Twin Strep-Tag/Strep Tactin was employed to establish a specific affinity system in the present study. We prepared a carnitine palmitoyltransferase 1A (CPT1A) MMSP by specifically linking Strep-tactin-modified silica gel with the Twin Strep-Tag on the CPT1A-oriented mitochondrial membrane. This Twin Strep-Tag/Strep Tactin modified CPT1A/MMC method exhibited remarkably better retention behavior, longer stationary phase lifespan, and higher screening specificity compared with previous MMC systems with glutaraldehyde immobilization. We adopted the CPT1A-specific MMC system in screening CPT1A ligands from traditional Chinese medicines, and successfully identified novel candidate ligands: ononin, isoliquiritigenin, and aloe-emodin, from Glycyrrhiza uralensis Fisch and Senna tora (L.) Roxb extracts. Biological assessments illustrated that the compounds screened promote CPT1A enzyme activity without affecting CPT1A protein expression, as well as effectively reduce the lipid droplets and triglyceride levels in the high fat induction HepG2 cells. The results suggest that we have developed an MMC system, which is promising for studying the bioaffinity of mitochondrial membrane proteins to candidate compounds. This system provides a platform for a key step in mitochondrial medicine discovery, especially for bioactive molecule screening from complex herbal extracts.

Induced Pluripotent Stem Cells and CRISPR-Cas9 Innovations for Treating Alpha-1 Antitrypsin Deficiency and Glycogen Storage Diseases.

Human induced pluripotent stem cell (iPSC) and CRISPR-Cas9 gene-editing technologies have become powerful tools in disease modeling and treatment. By harnessing recent biotechnological advancements, this review aims to equip researchers and clinicians with a comprehensive and updated understanding of the evolving treatment landscape for metabolic and genetic disorders, highlighting how iPSCs provide a unique platform for detailed pathological modeling and pharmacological testing, driving forward precision medicine and drug discovery. Concurrently, CRISPR-Cas9 offers unprecedented precision in gene correction, presenting potential curative therapies that move beyond symptomatic treatment. Therefore, this review examines the transformative role of iPSC technology and CRISPR-Cas9 gene editing in addressing metabolic and genetic disorders such as alpha-1 antitrypsin deficiency (A1AD) and glycogen storage disease (GSD), which significantly impact liver and pulmonary health and pose substantial challenges in clinical management. In addition, this review discusses significant achievements alongside persistent challenges such as technical limitations, ethical concerns, and regulatory hurdles. Future directions, including innovations in gene-editing accuracy and therapeutic delivery systems, are emphasized for next-generation therapies that leverage the full potential of iPSC and CRISPR-Cas9 technologies.

The Dual Impact of Artificial Intelligence in Healthcare: Balancing Advancements with Ethical and Operational Challenges

The synchronic and diachronic study of the evolution of Artificial Intelligence (AI) unveils one prominent fact that its effect can be traced in almost all fields such as healthcare industry. The growth is perceived holistically in software, hardware implementation, or application in these various fields. As the title suggests, the review will highlight the impact of AI on healthcare possibly in all dimensions including precision medicine, diagnostics, drug development, automation of the process, etc., explicating whether AI is a blessing or a curse or both. With the availability of enough data and analysis to examine the topic at hand, however, its application is still functioning in quite early stages in many fields, the present work will endeavour to provide an answer to the question. This paper takes a close look at how AI is transforming areas such as diagnostics, precision medicine, and drug discovery, while also addressing some of the key ethical challenges it brings. Issues like patient privacy, safety, and the fairness of AI decisions are explored to understand whether AI in healthcare is a positive force, a potential risk, or perhaps both.

Virtual screening of natural products to enhance melanogenosis.

Natural products have long been an important source of inspiration for medicinal chemistry and drug discovery. In the cosmetic field, they remain the major elements of the composition and serve as marketing asset. Recent research showed the implication of salt-inducible kinases on the melanin production in skin via MITF regulation. Finding new potent modulators on such target could open the way to several cosmetic applications to attenuate visible signs of photoaging and improve the tan without sun. Since virtual screening can be a powerful tool for detecting hit compounds in the early stages of a drug discovery process, we applied this method on salt-inducible kinase 2 to discover potential interesting compounds. Here, we present the different steps from the construction of a database of natural products, to the validation of a docking protocol and the results of the virtual screening. Hits from the screening were tested in vitro to confirm their efficiency and results are discussed.

Design and Synthesis of Novel β-Carboline-Bisindole Hybrids as Potential Anticancer Agents.

We are reporting a short and convenient pathway for the synthesis of novel β-carboline-bisindole hybrid compounds from relatively cheap and commercially available chemicals such as tryptamine, dialdehydes and indoles. These newly designed compounds can also be prepared in high yields with the tolerance of many functional groups under mild conditions. Notably, these β-carboline-bisindole hybrid compounds exhibited some promising applications as anticancer agents against the three common cancer cell lines MCF-7 (breast cancer), SK-LU-1 (lung cancer), and HepG2 (liver cancer). The two best compounds 5 b and 5 g inhibited the aforementioned cell lines with the same IC50 range of the reference Ellipticine at less than 2 μM. A molecular docking study to gain more information about the interactions between the synthesized molecules and the kinase domain of the EGFR was performed. Therefore, this finding can have significant impacts on the development of future research in medicinal chemistry and drug discovery.

An Overview of the Pharmacological Activities and Synthesis of Benzothiophene Derivatives.

One important class of organic compounds having many uses, especially in medical chemistry, is benzothiophene and its derivatives. This review examines the biological activity of benzothiophene derivatives and summarizes the synthetic methods used in their production. The effectiveness of several synthetic pathways, such as cyclization techniques, functional group modifications, and reactions catalyzed by transition metals, in gaining access to benzothiophene scaffolds has been examined. Additionally, a broad spectrum of therapeutic domains, such as antiinflammatory, antibacterial, antidiabetic, anticancer, antimicrobial, anti-leishmanial, antifungal, antimalarial, and antitubercular activities, are covered by the pharmacological activities that are being explored. The synthesis and pharmacological potential of benzothiophene derivatives are well-explained in this thorough review, which opens up new options for medicinal chemistry and drug discovery study. Overall, this study is a useful resource for scientists working on drug development and discovery as it sheds light on the pharmacological potential of benzothiophene derivatives. This review includes the synthesis and bioactivities of the years 2002-2024. The goal of this review is to compile the existing information on benzothiophene derivatives and provide guidance for future research and development as well as insights into their possible medicinal uses.

Synthesis of 18F‐labeled Aryl Trifluoromethyl Sulfones, ‐Sulfoxides, and ‐Sulfides for Positron Emission Tomography

AbstractPositron emission tomography (PET) is becoming increasingly important in nuclear medicine and drug discovery. To date, the development of many potential PET tracers is hampered by the lack of suitable synthetic pathways for their preparation. This is particularly true for the highly desired radiolabeling of compounds bearing [18F]CF3‐groups. For instance, S(O)nCF3‐groups (n=0, 1, 2) serve as structural motif in a range of biologically active compounds, but their radiosynthesis remains largely unprecedented (for n=1, 2). Herein, we describe general methods for the radiosynthesis of 18F‐labeled aryl trifluoromethyl sulfones, ‐sulfoxides, and ‐sulfides. All three methods are operationally straightforward, start from widely available precursors, i.e., sulfonyl fluorides and thiophenols, and make use of the recently established [18F]Ruppert‐Prakash reagent. Further, the syntheses display good functional group tolerance as demonstrated by the 18F‐labeling of more than 40 compounds. The applicability of the new method is demonstrated by the radiolabeling of three bioactive molecules, optionally to be used as PET tracers. In a broader context, this work presents a substantial expansion of the chemical space of radiofluorinated structural motifs to be used for the development of new PET tracers.

Synthesis of 18F-labeled Aryl Trifluoromethyl Sulfones, -Sulfoxides, and -Sulfides for Positron Emission Tomography.

Positron emission tomography (PET) is becoming increasingly important in nuclear medicine and drug discovery. To date, the development of many potential PET tracers is hampered by the lack of suitable synthetic pathways for their preparation. This is particularly true for the highly desired radiolabeling of compounds bearing [18F]CF3-groups. For instance, S(O)nCF3-groups (n=0, 1, 2) serve as structural motif in a range of biologically active compounds, but their radiosynthesis remains largely unprecedented (for n=1, 2). Herein, we describe general methods for the radiosynthesis of 18F-labeled aryl trifluoromethyl sulfones, -sulfoxides, and -sulfides. All three methods are operationally straightforward, start from widely available precursors, i.e., sulfonyl fluorides and thiophenols, and make use of the recently established [18F]Ruppert-Prakash reagent. Further, the syntheses display good functional group tolerance as demonstrated by the 18F-labeling of more than 40 compounds. The applicability of the new method is demonstrated by the radiolabeling of three bioactive molecules, optionally to be used as PET tracers. In a broader context, this work presents a substantial expansion of the chemical space of radiofluorinated structural motifs to be used for the development of new PET tracers.

CRISPR-Based Therapies: Revolutionizing Drug Development and Precision Medicine.

With the discovery of CRISPR-Cas9, drug development and precision medicine have undergone a major change. This review article looks at the new ways that CRISPR-based therapies are being used and how they are changing the way medicine is done. CRISPR technology's ability to precisely and flexibly edit genes has opened up new ways to find, validate, and develop drug targets. Also, it has made way for personalized gene therapies, precise gene editing, and advanced screening techniques, all of which hold great promise for treating a wide range of diseases. In this article, we look at the latest research and clinical trials that show how CRISPR could be used to treat genetic diseases, cancer, infectious diseases, and other hard-to-treat conditions. However, ethical issues and problems with regulations are also discussed in relation to CRISPR-based therapies, which shows how important it is to use them safely and responsibly. As CRISPR continues to change how drugs are made and used, this review shines a light on the amazing things that have been done and what the future might hold in this rapidly changing field.

Clinical Trial Management System using Blockchain for Secure and Efficient Record Keeping

In today’s developing environment, there is always a need for upgradation to easier lifestyle among people. Technology has improved in almost all areas of concern to facilitate people’s work. But even today, there is no efficient tool for managing Clinical Trial records. Clinical Trial records management is considered to be an important job when it comes to discovery of new medicines into the market. It is important to monitor the behaviour medicines for different group of people, at different locations, different age groups and gender. Only when the medicine’s behaviour is known, it can be administered to patients of several concerns. There are various EHMS used in hospitals to manage their data. But it should also be noted that, it is important to secure the data from theft or modification. Using Blockchain technology is one of the best ways to secure data from theft or modification. Clinical Trial Management system using Blockchain can be an efficient way to store trial reports safe.